Novo Nordisk introduced its plan to make use of its Commissioner’s Nationwide Precedence Assessment Voucher (CNPV) on its 7.2 mg Wegovy injectable, meant to be used with a diminished calorie weight loss plan and elevated bodily exercise for persistent weight administration in adults with weight problems.
The corporate submitted its supplemental New Drug Utility (sNDA) for its larger dose semaglutide injectable for assessment to FDA and underneath the CNPV, the assessment course of is expedited to simply 1-2 months, following FDA’s approval of the sNDA.1
“Our pipeline is quickly increasing to satisfy the wants of individuals dwelling with weight problems, and this submission, underneath the FDA’s new expedited assessment program, marks an thrilling step ahead,” stated Anna Windle, PhD, senior vp, medical improvement, medical and regulatory affairs, Novo Nordisk. “If authorised, semaglutide 7.2 mg would deliver sufferers and healthcare professionals a brand new possibility for larger weight reduction potential, additional underlining the efficacy that the semaglutide molecule can deliver. We stay up for working with the FDA to deliver this fast-tracked choice to the weight problems group.”
Wegovy was named as one of many first 15 medicine within the precedence assessment pilot program, granting Novo Nordisk the flexibility to acquire a voucher that allows FDA to speed up the drug assessment course of from 10-12 months to simply 1-2 months.2
Different medicine included in this system embrace:
- Pergoveris for infertility
- Teplizumab for Sort I diabetes
- Cytisinicline for nicotine vaping habit
- DB-OTO for deafness
- Cenegermin-bkbj for blindness
- RMC-6236 for pancreatic most cancers
- Bitopertin for porphyria
- Ketamine for home manufacturing of a important drug for basic anesthesia
- Augmentin XR for home manufacturing of a standard antibiotic
- Hernexeos for HER2 lung most cancers
- Sirturo for drug-resistant tuberculosis in younger kids
- Jemperli for rectal most cancers
- Casgevy or sickle cell illness
- Orforglipron for weight problems and associated well being circumstances
The sNDA contains outcomes from the Part III STEP UP trial, a randomized, double-blind, placebo-controlled and active-controlled superiority trial, evaluating the efficacy and security of once-weekly semaglutide 7.2 mg injectables, in comparison with each placebo and semaglutide 2.4 mg, as an adjunct to life-style intervention.1 The examine’s major goal was to display superiority of semaglutide 7.2 mg in opposition to placebo with respect to the share change in physique weight, together with the proportion of members with weight lack of 5% or larger.1
Different findings from the examine confirmed that gastrointestinal antagonistic occasions have been extra frequent with semaglutide 7.2 mg in comparison with 2.4 mg or placebo, as was dysaesthesia. Moreover, critical antagonistic occasions have been reported by 6.8% of members with semaglutide 7.2 mg, 10.9% with semaglutide 2.4 mg, and 5.5% with placebo.2
The confirmatory secondary endpoints of the examine included measuring the proportion of members reaching larger than or equal to 10%, 15%, 20% and 25% weight reduction with semaglutide 7.2 mg in comparison with those that have been administered the placebo. The trial was carried out over a 72-week interval and included a affected person inhabitants of 1,407 adults with weight problems whereas sufferers with diabetes have been excluded.1
1. Novo Nordisk information for FDA approval of a better dose of Wegovy® injection 7.2 mg PR Newswire.November 26, 2025.
2. FDA Continues to Develop Nationwide Precedence Voucher Program. Pharmaceutical Govt. November 7, 2025.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a world community of future-focused thinkers.
Unlock tomorrow’s tendencies in the present day: learn extra, subscribe to our publication, and grow to be a part of the NextTech group at NextTech-news.com
